1623-92-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Phenoxybenzenesulfonyl chloride is used as a reagent for the synthesis of various organic compounds, particularly in the production of sulfonamide derivatives. These derivatives are widely used as antibacterial agents and in the treatment of various medical conditions.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Phenoxybenzenesulfonyl chloride serves as a key building block for the development of new compounds with potential applications in agriculture, such as pesticides and herbicides.
Used in Research and Development:
4-Phenoxybenzenesulfonyl chloride is utilized in research and development for the synthesis of novel compounds with potential pharmaceutical applications. Its ability to form carbon-carbon and carbon-heteroatom bonds makes it a valuable tool in chemical synthesis for exploring new therapeutic agents and drug candidates.
Used in Chemical Synthesis:
As a versatile reagent, 4-Phenoxybenzenesulfonyl chloride is employed in chemical synthesis for the formation of carbon-carbon and carbon-heteroatom bonds. This property allows chemists to create a wide range of compounds with diverse structures and functionalities, contributing to the advancement of organic chemistry and the development of new materials and pharmaceuticals.

Upstream product

• 20241-57-0 para-phenoxybenzenesulfonic acid 
• 101-84-8 diphenylether 
• 101-55-3 4-Bromodiphenyl ether 
• 79-37-8 oxalyl dichloride 
• 83863-63-2 2-Dibenzofuransulfonic acid 

Downstream Products

• 123045-62-5 4-phenoxybenzenesulfonamide 
• 113113-66-9 1,2-bis(4-phenoxyphenyl)disulfane 
• 106-46-7 para-dichlorobenzene 
• 108-90-7 chlorobenzene 
• 22525-89-9 p-Phenoxybenzolsulfonylhydrazid 
• 70155-68-9 4-Phenoxybenzolsulfonylazid 
• 61404-92-0 4-(4-nitro-phenoxy)-benzenesulfonyl chloride 
• 70155-65-6 N,N-Dimethyl-4-phenoxybenzolsulfonamid 
• 70155-66-7 N',N'-Dimethyl-4-phenoxybenzolsulfonohydrazid 
• 70155-64-5 4-Phenoxy-N'-phenylbenzolsulfonohydrazid 
• 186529-58-8 (Z)-7-[(1S,2R,3R,4R)-3-(4-Phenoxy-benzenesulfonylamino)-bicyclo[2.2.1]hept-2-yl]-hept-5-enoic acid methyl ester 
• 186551-87-1 N-[1-(3-cyano-benzyl)-2-oxo-pyrrolidin-3-yl]-4-phenoxy-benzenesulfonamide 
• 478945-53-8 N-isobutyl-N-(2-oxo-tetrahydro-thiophen-3-yl)-4-phenoxy-benzenesulfonamide 
• 607707-88-0 (2R,4'S,4S,5'R)-(4-phenoxybenzenesulfonylamino)-(2',2',2,2-tetramethyl-[4',4]bis[[1,3]dioxolanyl]-5'-yl)-acetic acid methyl ester 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity

On the basis of the strategy of “multifunctional drugs”, a series of novel matrix metalloproteinase inhibitors (MMPIs) containing benzofuroxan scaffold as a nitric oxide donor were designed, synthesized and evaluated. All synthesized compounds, especially 16a, exhibited potent MMP-2,9 inhibitory activities, anti-proliferative activities and could produce high levels of NO in Hela cells. They were also evaluated for both of their anti-invasion and anti-angiogenesis effects. Furthermore, compared with LY52, 16a demonstrated competitive antitumor activity in vivo. These hybrid NO-MMPIs might offer suitable scaffolds to develop valuable MMP inhibitors for the further discovery of novel anti-cancer drugs.

Fragment-Based Design, Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids as Selective Mcl-1 Inhibitors

Based on a known selective Mcl-1 inhibitor, 6-chloro-3-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-1H-indole-2-carboxylic acid, we applied a fragment-based approach to obtain new molecules that extended into the p1 pocket of the BH3 groove and then exhibited binding selectivity for the Mcl-1 over the Bcl-2 protein. After we deconstructed the 1H-indole-2-carboxylic acid from the parental molecule, a benzenesulfonyl was substituted at the 1-position to adopt a geometry preferred for accessing the p1 pocket according to the binding mode of the parental molecule identified by X-ray crystallography. A linear relationship between the free energy of ligand binding (ΔG) and the count of non-hydrogen heavy atoms (HAC) was maintained during the molecular growing to occupy the p1 pocket. Finally, we not only obtained compound 12 with a 7.5-fold selectivity to Mcl-1 (Ki = 0.48 μM by fluorescence polarization) over Bcl-2 (Ki = 3.6 μM), but also provided evidence that additional occupation of the p1 pocket is more favorable for Mcl-1 than for Bcl-2 binding, and contributes more to Mcl-1 inhibition than occupation of the p2 pocket. Compound 12 exhibited a selective killing ability on Mcl-1-dependent cancer cells.

SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growthinvitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.

Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors

As the matrix metalloproteinases (MMPs) can be massively up-regulated in degenerative tissues and degrade the extracellular matrix, these key enzymes are promising targets for the therapy of cancer and other degenerative diseases. Here, we are presenting a series of new non-peptidic hydroxamate-based matrix metalloproteinase inhibitors, MMPIs, incorporating the iminodiacetic (IDA) hydroxamic acid scaffold, as mimics of truncated peptidic MMPIs. A series of alkylaryl and sulfonylaryl groups, on the IDA basic scaffold, was investigated with the aim of improving potency and selectivity against MMPs involved in degenerative diseases. The sulfonamide based IDA derivatives studied (compounds B1-B3) showed to be potent (nM range) against deep S1′ pocket MMPs enzymes (i.e., MMP-2).

Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists

The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.

Facile one-pot synthesis of aromatic and heteroaromatic sulfonamides

A series of arene and heteroarene sulfonamides were prepared in one vessel from aryl and heteroaryl bromides via conversion into the corresponding Grignard reagents using either magnesium or isopropylmagnesium chloride and subsequent reaction with sulfur dioxide, sulfuryl chloride, and an amine.

Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives

Novel prostaglandin D2 (PGD2) receptor antagonists were synthesized as a potential new class of antiallergic agents having a bicyclo[2.2.1] heptane ring system with sulfonamide groups. Some of them exhibit extremely potent antagonism of the PGD2 receptor in radioligand binding and cAMP formation assays with IC50 values below 50 nM and much less antagonism of TXA2 and PGI2 receptors. These potent PGD2 receptor antagonists, when given orally, dramatically suppress various allergic inflammatory responses such as increased vascular permeability in allergic rhinitis, conjunctivitis, and asthma models. The excellent pharmacological profiles of PGD2 receptor antagonists, originally synthesized in our laboratories, are of potentially great clinical significance. This study also provides experimental evidence suggesting that PGD2 plays an important role in the pathogenesis of allergic diseases.

Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof

The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases

Compounds of formula (I) wherein W is —OH or —NHOH; X is an optionally substituted heterocycle, NR1SO2R2, heterocyclylalkythio, CONR2R3or NR1COR2; Y, Z, R1-R3and n are as defined in the application. Compounds (I) are inhibitors of matrix-degrading metalloproteinases and are use for the treatment of related conditions.

Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their pharmaceutical uses

The present invention relates to compounds of formula I:wherein Ar is an aryl group or a heteroaryl group; X is -NH-OH or -OH; R1 is H, -CH(R3)(R4), -C(O)R3, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, wherein R3 is